Z-1018 not checked
Dynavax Technologies Corporation
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Shingles, Herpes Zoster, Vaccine-Preventable Diseases
- Main trialPhase 1/2
- “This is a randomized, active-controlled, observer-blinded, dose-escalation multi-center trial of 2 doses of an investigational HZ vaccine (Z-1018) in approximately 764 healthy adults.”In the company’s words, NCT06569823 on ClinicalTrials.gov
Other drugs for Shingles
- HZ/su vaccineGSK · Phase 3
- Recombinant Zoster VaccineMAXVAX Biotechnology Limited Liability Company · Phase 3
- CVI-VZV-001Aribio Lab Co., Ltd. · Phase 2
- SYS6017CSPC · Phase 2
- SYS6052CSPC · Phase 1/2
- HZ VaccineShenzhen Shenxin Biotechnology Co., Ltd · Phase 2
Coming up1
- Jun 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | Jun 2027 | Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over | |
| Phase 1Completed | 20 Oct 2022 | Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026